Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $13,149.52 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 328 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $40.09, for a total value of $13,149.52. Following the transaction, the chief executive officer owned 38,872 shares in the company, valued at $1,558,378.48. This represents a 0.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Jack Bendheim also recently made the following trade(s):

• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.93, for a total value of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.19, for a total value of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.06, for a total value of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.77, for a total transaction of $143,510.40.
• On Tuesday, November 25th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $43.93, for a total transaction of $309,267.20.
• On Wednesday, November 26th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.02, for a total transaction of $232,425.60.
• On Monday, November 17th, Jack Bendheim sold 5,280 shares of Phibro Animal Health stock. The shares were sold at an average price of $44.56, for a total transaction of $235,276.80.
• On Thursday, November 13th, Jack Bendheim sold 8,801 shares of Phibro Animal Health stock. The stock was sold at an average price of $44.47, for a total transaction of $391,380.47.
• On Wednesday, November 12th, Jack Bendheim sold 21,536 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.23, for a total transaction of $974,073.28.
• On Monday, November 10th, Jack Bendheim sold 38,303 shares of Phibro Animal Health stock. The stock was sold at an average price of $45.29, for a total value of $1,734,742.87.

Phibro Animal Health Price Performance

NASDAQ:PAHC opened at $39.44 on Friday. The stock has a 50 day moving average of $40.83 and a two-hundred day moving average of $36.58. Phibro Animal Health Corporation has a 12 month low of $16.16 and a 12 month high of $46.42. The firm has a market cap of $1.60 billion, a P/E ratio of 23.76, a price-to-earnings-growth ratio of 1.12 and a beta of 0.79. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were issued a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. Phibro Animal Health’s dividend payout ratio is presently 28.92%.

Trending Headlines about Phibro Animal Health

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Analyst upgrades and forecasts lifted — Zacks Research has been raising Q4/Q1 and FY2027–FY2028 EPS estimates and recently moved the stock to a “Strong-Buy.” JPMorgan also raised its target to $50 and Weiss reiterated a buy. These institutional research moves reinforce the bullish case tied to above-consensus results and multi-year growth expectations.
• Positive Sentiment: Solid fundamentals and recent earnings beat — Phibro reported an upside Q3 result (Nov. 5) with EPS and revenue above estimates and provided FY2026 guidance of $2.64–$2.81, supporting the growth narrative for investors.
• Neutral Sentiment: Comparative research note — Zacks published a comparative piece weighing PAHC versus Boston Scientific (BSX) for value investors; useful context but not a direct catalyst. Read More.
• Neutral Sentiment: Dividend and institutional ownership — Phibro pays a modest quarterly dividend ($0.12, $0.48 annualized, ≈1.2% yield) and ~99% of shares are institutionally held, which can mute volatility but concentrate downside if large holders shift positions.
• Neutral Sentiment: Positive growth write-up — A Zacks feature highlights three reasons growth investors might favor PAHC, reinforcing interest from growth-oriented investors. Read More.
• Negative Sentiment: Insider selling by CEO — Jack Bendheim has been an active seller in recent months (most recently 328 shares sold at ~$40.09), adding to a string of insider disposals. Continued insider sales can weigh on investor sentiment even when sales may be for personal-liquidity reasons. Read More.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on PAHC shares. Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 9th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, JPMorgan Chase & Co. boosted their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $31.40.

Hedge Funds Weigh In On Phibro Animal Health

A number of institutional investors have recently bought and sold shares of the company. Hughes Financial Services LLC purchased a new stake in shares of Phibro Animal Health in the 3rd quarter valued at approximately $40,000. Financial Management Professionals Inc. purchased a new stake in shares of Phibro Animal Health during the 2nd quarter valued at approximately $32,000. iSAM Funds UK Ltd acquired a new position in Phibro Animal Health in the third quarter valued at approximately $61,000. Advisory Services Network LLC acquired a new position in Phibro Animal Health in the third quarter valued at approximately $96,000. Finally, EverSource Wealth Advisors LLC grew its position in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after acquiring an additional 2,685 shares during the period. 99.34% of the stock is owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.